Exact Therapeutics AS (FRA:56F) Institutional Ownership: 1.29% (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:56F Exact Therapeutics AS FRA:56F
21 GF Score
Price €0.02
! 2 Warning Signs
View Full Analysis

What is Exact Therapeutics AS Institutional Ownership?

Exact Therapeutics AS FRA:56F +7.69% 21 Institutional Ownership is 1.29% as of Jul. 24, 2026. GuruFocus rates FRA:56F with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Exact Therapeutics AS's institutional ownership is 1.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Exact Therapeutics AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Exact Therapeutics AS's Float Percentage Of Total Shares Outstanding is 0.00%.

Exact Therapeutics AS Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Exact Therapeutics AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Therapeutics AS Institutional Ownership Chart

Exact Therapeutics AS Historical Data

The historical data trend for Exact Therapeutics AS can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 1.14 2.27 2.27 2.27 2.27 2.27 2.27 1.29 1.29 1.29
FRA:56F
21GF Score
Exact Therapeutics AS FRA:56F
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exact Therapeutics AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.29% mean?
Exact Therapeutics AS (FRA:56F) has a Institutional Ownership of 1.29% as of Jul. 24, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Exact Therapeutics AS and its competitors.
Is Exact Therapeutics AS's Institutional Ownership too high?
Exact Therapeutics AS's current Institutional Ownership is 1.29%. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's Institutional Ownership compare to VRTX and REGN?
Exact Therapeutics AS's Institutional Ownership of 1.29% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Exact Therapeutics AS and its competitors. Exact Therapeutics AS's current Institutional Ownership is 1.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current Institutional Ownership of 1.29%. The current Institutional Ownership is 1.29%. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current Institutional Ownership is 1.29% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exact Therapeutics AS Business Description

Other Exchanges EXTX:Norway
Address Ostre Aker Vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score

Get the complete analysis for FRA:56F

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price